Wakamoto Pharmaceutical Co.,Ltd. (TYO:4512)
Japan · Delayed Price · Currency is JPY 307.00
+3.00 (0.99%)
Aug 7, 2025, 3:30 PM JST
Revance Therapeutics Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | 2003 - 2007 |
|---|---|---|---|---|---|---|
Period Ending | Mar '12 Mar 31, 2012 | Mar '11 Mar 31, 2011 | Mar '10 Mar 31, 2010 | Mar '09 Mar 31, 2009 | Mar '08 Mar 31, 2008 | 2003 - 2007 |
| 9,432 | 9,669 | 9,777 | 10,080 | 10,169 | Upgrade | |
Revenue Growth (YoY) | -2.45% | -1.10% | -3.01% | -0.87% | -1.54% | Upgrade |
Cost of Revenue | 4,352 | 4,493 | 4,097 | 3,853 | 3,547 | Upgrade |
Gross Profit | 5,080 | 5,176 | 5,680 | 6,227 | 6,622 | Upgrade |
Selling, General & Admin | 4,744 | 4,884 | 4,799 | 4,969 | 4,985 | Upgrade |
Research & Development | 792 | 997 | 874.97 | 1,005 | 990.03 | Upgrade |
Other Operating Expenses | - | - | -3 | -1 | -12 | Upgrade |
Operating Expenses | 5,580 | 5,932 | 5,703 | 6,023 | 6,012 | Upgrade |
Operating Income | -500 | -756 | -22.89 | 203.52 | 610.25 | Upgrade |
Interest Expense | -28 | -27 | -19.05 | - | - | Upgrade |
Interest & Investment Income | 34 | 33 | 34.66 | 57.26 | 33.83 | Upgrade |
Other Non Operating Income (Expenses) | 258 | 191 | 176.47 | 342.84 | 263.55 | Upgrade |
EBT Excluding Unusual Items | -236 | -559 | 169.2 | 603.63 | 907.63 | Upgrade |
Merger & Restructuring Charges | - | - | -38 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -24 | -34 | -3.32 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 125 | -9 | - | - | - | Upgrade |
Asset Writedown | -13 | -24 | -9.81 | -9.41 | -14.44 | Upgrade |
Other Unusual Items | 20 | - | - | 13.16 | -175.94 | Upgrade |
Pretax Income | -128 | -626 | 141 | 607.37 | 717.26 | Upgrade |
Income Tax Expense | 94 | -201 | 92.48 | 256.01 | 310.37 | Upgrade |
Net Income | -222 | -425 | 48.52 | 351.36 | 406.89 | Upgrade |
Net Income to Common | -222 | -425 | 48.52 | 351.36 | 406.89 | Upgrade |
Net Income Growth | - | - | -86.19% | -13.65% | -14.72% | Upgrade |
Shares Outstanding (Basic) | 35 | 35 | 34 | 34 | 34 | Upgrade |
Shares Outstanding (Diluted) | 35 | 35 | 34 | 34 | 34 | Upgrade |
Shares Change (YoY) | 0.59% | 0.53% | -0.11% | 1.62% | 4.30% | Upgrade |
EPS (Basic) | -6.38 | -12.29 | 1.41 | 10.20 | 12.00 | Upgrade |
EPS (Diluted) | -6.38 | -12.29 | 1.41 | 10.20 | 12.00 | Upgrade |
EPS Growth | - | - | -86.18% | -15.02% | -18.23% | Upgrade |
Free Cash Flow | 198 | -121 | -2,120 | -1,001 | 248.84 | Upgrade |
Free Cash Flow Per Share | 5.69 | -3.50 | -61.62 | -29.07 | 7.34 | Upgrade |
Dividend Per Share | - | - | 5.000 | 5.000 | 5.000 | Upgrade |
Gross Margin | 53.86% | 53.53% | 58.10% | 61.77% | 65.12% | Upgrade |
Operating Margin | -5.30% | -7.82% | -0.23% | 2.02% | 6.00% | Upgrade |
Profit Margin | -2.35% | -4.40% | 0.50% | 3.49% | 4.00% | Upgrade |
Free Cash Flow Margin | 2.10% | -1.25% | -21.69% | -9.93% | 2.45% | Upgrade |
EBITDA | 508 | 448 | 697.21 | 756.93 | 1,123 | Upgrade |
EBITDA Margin | 5.39% | 4.63% | 7.13% | 7.51% | 11.04% | Upgrade |
D&A For EBITDA | 1,008 | 1,204 | 720.1 | 553.41 | 512.27 | Upgrade |
EBIT | -500 | -756 | -22.89 | 203.52 | 610.25 | Upgrade |
EBIT Margin | -5.30% | -7.82% | -0.23% | 2.02% | 6.00% | Upgrade |
Effective Tax Rate | - | - | 65.59% | 42.15% | 43.27% | Upgrade |
Advertising Expenses | 1,179 | 1,095 | 1,201 | 1,277 | 392.81 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.